1887
Rapid communication Open Access
Like 0

Abstract

In the WHO European Region, COVID-19 non-pharmaceutical interventions continued slowing influenza circulation in the 2021/22 season, with reduced characterisation data. A(H3) predominated and, in some countries, co-circulated with A(H1)pdm09 and B/Victoria viruses. No B/Yamagata virus detections were confirmed. Substantial proportions of characterised circulating virus subtypes or lineages differed antigenically from their respective northern hemisphere vaccine components. Appropriate levels of influenza virus characterisations should be maintained until the season end and in future seasons, when surveillance is adapted to integrate SARS-CoV-2.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.15.2200255
2022-04-14
2022-05-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2022.27.15.2200255
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/15/eurosurv-27-15-4.html?itemId=/content/10.2807/1560-7917.ES.2022.27.15.2200255&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation - Summary Europe, February 2022. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/influenza-virus-characterisation-summary-europe-february-2022
  2. Adlhoch C, Mook P, Lamb F, Ferland L, Melidou A, Amato-Gauci AJ, et al. , European Influenza Surveillance Network. Very little influenza in the WHO European Region during the 2020/21 season, weeks 40 2020 to 8 2021. Euro Surveill. 2021;26(11).  https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100221  PMID: 33739256 
  3. European Centre for Disease Prevention and Control (ECDC). Assessment of the further spread and potential impact of the SARS-CoV-2 Omicron variant of concern in the EU/EEA, 19th update - 27 January 2022. ECDC: Stockholm; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-and-impact-sars-cov-2-delta-variant
  4. European Centre for Disease Prevention and Control, World Health Organization Regional Office for Europe (ECDC, WHO/Europe). European External Influenza Virus Quality Assessment Programme 2022. Stockholm and Copenhagen: ECDC and WHO/Europe; 2022. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/20220204-report-EEIQAP-2020.pdf
  5. European Centre for Disease Prevention and Control, World Health Organization Regional Office for Europe (ECDC, WHO/Europe). European external quality assessment programme for influenza virus – 2018. Stockholm and Copenhagen: ECDC and WHO/Europe; 2019. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/influenza-virus-external-quality-assessment-2018.pdf
  6. World Health Organization (WHO). WHO Collaborating Centres and their Terms of Reference. Geneva: WHO. [Accessed 10 Apr 2022]. Available from: https://www.who.int/initiatives/global-influenza-surveillance-and-response-system/who-collaboration-center-erl
  7. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. Geneva: WHO; 2022. Available from: https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2022-2023/202202_recommendation.pdf?sfvrsn=5c88e006_13&download=true
  8. Melidou A, Pereyaslov D, Hungnes O, Prosenc K, Alm E, Adlhoch C, et al. , WHO European Region influenza surveillance network, WHO European Region Influenza Surveillance Network author list. Virological surveillance of influenza viruses in the WHO European Region in 2019/20 - impact of the COVID-19 pandemic. Euro Surveill. 2020;25(46).  https://doi.org/10.2807/1560-7917.ES.2020.25.46.2001822  PMID: 33213683 
  9. European Centre for Disease Prevention and Control, World Health Organization Regional Office for Europe (ECDC, WHO/Europe). Flu News Europe, Joint ECDC-WHO/Europe weekly influenza update. Stockholm and Copenhagen: ECDC, and WHO/Europe; 2022. Available from: https://flunewseurope.org/
  10. European Centre for Disease Prevention and Control (ECDC). COVID-19 surveillance guidance - Transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-surveillance-guidance
  11. World Health Organization (WHO). End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance. Geneva: WHO; 2022. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Integrated_sentinel_surveillance-2022.1
  12. Chung JR, Kim SS, Kondor RJ, Smith C, Budd AP, Tartof SY, et al. Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(10):365-70.  https://doi.org/10.15585/mmwr.mm7110a1  PMID: 35271561 
  13. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2022 southern hemisphere influenza season. Geneva: WHO; 2021. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-southern-hemisphere-influenza-season
  14. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2020 southern hemisphere influenza season. Geneva: WHO; 2019 Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2020-southern-hemisphere-influenza-season
  15. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2020-2021 northern hemisphere influenza season. Geneva: WHO; 2020. Available at: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2020-2021-northern-hemisphere-influenza-season
/content/10.2807/1560-7917.ES.2022.27.15.2200255
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error